Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aegerion Pharmaceuticals has filed with the US Securities and Exchange Commission for an initial public offering of common stock.
Subscribe to our email newsletter
The biopharmaceutical firm said the offering would raise up to $86.25 million, although the company has not revealed how many shares it is planning to sell in the offering.
New Jersey-based Aegerion said it plans to use the proceeds from the IPO for repayment of debt and to fund the continued clinical development of cardiovascular drugs AEGR-733 and AEGR-427, as well as for general corporate purposes.
Lehman Brothers Inc., CIBC World Markets Corp, Thomas Weisel Partners LLC, CE Unterberg, Towbin LLC are listed as the underwriters.